Figure 2From: Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patientsTrastuzumab-mediated ADCP of healthy volunteers and breast cancer patients. The extent of ADCP was determined by flow cytometry and is shown in % of total tumor cell counts. An E/T ratio of 25:1 was used. White boxplots represent healthy volunteers, light grey adjuvant, grey metastatic and dark grey trastuzumab naive (t-naive) breast cancer patients. The addition of trastuzumab is indicated at the bottom (-/+).Back to article page